The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life

NCT ID: NCT05195515

Last Updated: 2023-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bladder Cancer prognosis, treatment, and subsequent morbidity and mortality vary between the different stages, thus resulting in a different impact on patients' lives. There are some well known late effects of the treatments for bladder cancer, but the knowledge of their impact on patients Quality of Life is sparse. This study aims to determine the prevalence of late effects impact on Quality of Life and potential risk factors for impairment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients are eligible if they are referred to a hospital in the Central Region Denmark, due to hematuria between 01/01/2022 and 01/01/2023
* Ability to understand written and oral Danish

Exclusion Criteria

* Known Alzheimers disease
* Diagnosed other causes explaining the hematuria
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role collaborator

National Research Center for Survivorship and Late Adverse Effects Following Pelvic Organ Cancer, Denmark

UNKNOWN

Sponsor Role collaborator

Aarhus University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jørgen Bjerggaard Jensen

Professor, DMSc

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jørgen Bjerggaard Jensen, Professor

Role: PRINCIPAL_INVESTIGATOR

Department of Urology, Aarhus University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Urology, Aarhus University Hospital

Aarhus N, , Denmark

Site Status

Department of Urology, Regional Hospital Gødstrup

Gødstrup, , Denmark

Site Status

Department of Urology, Regional Hospital Horsens

Horsens, , Denmark

Site Status

Department of Urology, Regional Hospital Randers

Randers, , Denmark

Site Status

Department of Urology, Regional Hospital Viborg

Viborg, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CONQUER

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Image-Guided Tumorboost of Bladder Cancer
NCT00963404 COMPLETED PHASE1/PHASE2